Arbutus Biopharma (ABUS) Gains from Investment Securities (2015 - 2026)
Arbutus Biopharma (ABUS) posted Gains from Investment Securities of $209000.0 for Q1 2026, up 107.87% sequentially from -$2.7 million in Q4 2025, and down 30.1% YoY from $299000.0 in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Gains from Investment Securities (2015 - 2026) Analysis & Trends
Arbutus Biopharma has reported Gains from Investment Securities for 12 years, with the latest figure at $209000.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 30.1% year-over-year to $209000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 169.97% YoY) and the FY2025 annual result came in at -$1.8 million, down 169.71% from the prior year.
- Gains from Investment Securities climbed to $209000.0 in Q1 2026 per ABUS's latest filing, from -$2.7 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $1.9 million in Q4 2024 and troughed at -$2.7 million in Q4 2025.
- A 5-year average of $194470.6 and a median of $215000.0 in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities soared 733.68% in 2022, then slumped 405.77% in 2023.
- Over 5 years, Gains from Investment Securities stood at $1.6 million in 2022, then plunged by 85.89% to $227000.0 in 2023, then surged by 732.6% to $1.9 million in 2024, then plunged by 240.58% to -$2.7 million in 2025, then soared by 107.87% to $209000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $209000.0, -$2.7 million, and $227000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 213,000.00 |
| Mar 31, 2026 | 209,000.00 |
| Dec 31, 2025 | -2.66 Mn |
| Sep 30, 2025 | 268,000.00 |
| Jun 30, 2025 | 260,000.00 |
| Mar 31, 2025 | 299,000.00 |
| Dec 31, 2024 | 1.89 Mn |
| Sep 30, 2024 | 344,000.00 |
| Jun 30, 2024 | 211,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Sep 30, 2023 | 205,000.00 |
| Jun 30, 2023 | -636,000.00 |
| Mar 31, 2023 | 273,000.00 |
| Dec 31, 2022 | 1.61 Mn |
| Sep 30, 2022 | 215,000.00 |
| Jun 30, 2022 | 208,000.00 |
| Mar 31, 2022 | 201,000.00 |
| Dec 31, 2021 | 193,000.00 |
| Sep 30, 2021 | 856,000.00 |